Moderna Inc. (MRNA)

21.44
NASDAQ : Health Technology
Prev Close 19.66
Day Low/High 19.70 / 21.47
52 Wk Low/High 13.03 / 22.75
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 328.95M
Market Cap 6.47B
EPS -0.80
Div & Yield N.A. (N.A)

Latest News

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Fitbit, Moderna, Tilray, Exelixis, Maxar Technology, International Paper and more.

Moderna Announces Positive Interim Phase 1 Data For First Combination Vaccine Against The Respiratory Viruses HMPV And PIV3

Moderna Announces Positive Interim Phase 1 Data For First Combination Vaccine Against The Respiratory Viruses HMPV And PIV3

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim...

Moderna Announces Dosing Of The First Monoclonal Antibody Encoded By MRNA In A Clinical Trial

Moderna Announces Dosing Of The First Monoclonal Antibody Encoded By MRNA In A Clinical Trial

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase...

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Jim Cramer makes sense of this market action and has your game plan for next week.

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Bank of America, Kemet, Boston Beer, Diageo, Pilgrim's Pride, Tyson Foods, Moderna and more.

Fear of Missing Out Is the Main Driving Force in This Market

Fear of Missing Out Is the Main Driving Force in This Market

Stick to your methodology and don't let worry of underperformance push you to shift your approach.

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that...

Dr. John Mendlein To Transition To An Advisory Role At Moderna And Join Flagship Pioneering As An Executive Partner

Dr. John Mendlein To Transition To An Advisory Role At Moderna And Join Flagship Pioneering As An Executive Partner

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna only went public in December, and is already creating a buzz.

Moderna Shares Jump on Positive Cancer-Treatment Progress

Moderna Shares Jump on Positive Cancer-Treatment Progress

Report on positive results of new drugs to treat ovarian and other cancers sends shares higher.

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced recent updates to several of its...

Moderna To Provide Business And Pipeline Updates At The 2019 J.P. Morgan Healthcare Conference

Moderna To Provide Business And Pipeline Updates At The 2019 J.P. Morgan Healthcare Conference

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an...

It's a Two-Sided Market: Cramer's 'Mad Money' Recap (Monday 12/10/18)

It's a Two-Sided Market: Cramer's 'Mad Money' Recap (Monday 12/10/18)

There are two sides, or more, to every market story these days, Jim Cramer says.

Biotech Moderna Slides in Its Trading Debut

Biotech Moderna Slides in Its Trading Debut

Drug developing startup Moderna Inc. raises $604.3 million for an initial public offering running up to its expected Nasdaq debut Friday.

Moderna Announces Pricing Of Initial Public Offering

Moderna Announces Pricing Of Initial Public Offering

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of its initial public offering...

Marina Biotech And Mirna Therapeutics Amend License Agreement For The Development Of MicroRNA-based Therapeutics

Marina Biotech And Mirna Therapeutics Amend License Agreement For The Development Of MicroRNA-based Therapeutics

Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc.

5 Biggest Drug-Stock Losers of 2011

5 Biggest Drug-Stock Losers of 2011

Reading this list of stinkers incites a little Schadenfreude as one company fell 99.6%.

Encorium Group, MDRNA: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Monday's session.